Drugs / Fingolimod
Fingolimod
also known as
FTY720 · Gilenya · Fingolimod Hydrochloride · Fingolimod (as hydrochloride) · Fingolimod accord · Fingolimod hcl · Fingolimod hydrochlorid · Fingolimod mylan · +6 more
Small molecule targets RHOA via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | GILENYA | — | 2011-07-20 – 2018-05-11 | fda.gov ↗ |
| Approved | EU (EMA) | Gilenya | — | 2011-03-17 | europa.eu ↗ |
| Approved | US (FDA) | GILENYA | — | 2010-09-21 | fda.gov ↗ |
Trials 71 · started per year
today
US approved 2010
EU approved 2011
1
4
4
2
4
1
5
4
6
8
9
3
2
2
1
3
4
3
1
1
1
2
200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT04088630 | Aug 2020 → Jun 2023 | brain edema, intracerebral hemorrhage | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 0 | NCT03943498 | May 2019 → Dec 2020 | chemotherapy-induced neuropathy | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT02490930 | Jul 2015 → Sep 2017 | anaplastic astrocytoma, glioblastoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT03941743 | Dec 2019 → Jun 2020 | breast carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT00731523 | Jul → Aug 2008 | impaired renal function disease | Novartis | Completed | No outcome recorded |
| Phase 1 | NCT00416845 | Oct 2006 → Mar 2007 | — | Novartis | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06087965 | Oct 2023 → Jun 2025 | intracerebral hemorrhage | Tang-Du Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02061137 | Aug 2013 → Apr 2018 | Rett syndrome | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 215 trials | ||||||
| Phase 2 | NCT06424067 | May 2025 → May 2027 expected | non-small cell lung carcinoma, small cell lung carcinoma | Medical University of South Carolina | Recruiting | No outcome recorded |
| Phase 2 | NCT04675762 | Jan 2021 → Dec 2025 | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 2 | NCT04629872 | Nov 2020 → Dec 2022 | stroke disorder | Ning Wang, MD., PhD. | Unknown | No outcome recorded |
| Phase 2 | NCT04280588 | Feb → Jul 2020 | COVID-19 | First Affiliated Hospital of Fujian Medical University | Withdrawn | No outcome recorded |
| Phase 2 | NCT02956200 | Nov 2016 → Oct 2018 | ischemic stroke | Second Affiliated Hospital, School of Medicine, Zhejiang University | Withdrawn | No outcome recorded |
| Phase 2 | NCT01791192 | Nov 2013 → Oct 2014 | uveitis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT01786174 | Aug 2013 → Sep 2014 | amyotrophic lateral sclerosis | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01757691 | Aug 2013 → May 2014 | optic neuritis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02002390 | Oct 2012 → Oct 2014 | ischemic stroke | Tianjin Medical University General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00785083 | Sep 2008 → Feb 2009 | asthma | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00670449 | Apr 2008 → Apr 2012 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00537082 | Sep 2007 → Feb 2010 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00239798 | Nov 2004 → Nov 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00333138 | May 2003 → Apr 2011 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT00239902 | May 2002 → Nov 2004 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/33 trials | ||||||
| Phase 2/3 | NCT07220252 | Jul 2026 → Jan 2030 expected | multiple sclerosis | TG Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT01647880 | Jul 2013 → Apr 2016 | multiple sclerosis | Charite University, Berlin, Germany | Terminated | No outcome recorded |
| Phase 2/3 | NCT00099749 | Nov 2003 → Apr 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 322 trials | ||||||
| Phase 3 | NCT07483632 | Nov 2026 → Jul 2034 expected | multiple sclerosis | Biogen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT01941004 | Jun 2014 → May 2017 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01892722 | Jul 2013 → Jul 2017 overdue | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01625182 | Dec 2012 → Sep 2016 | chronic inflammatory demyelinating polyradiculoneuropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01633112 | Aug 2012 → Apr 2018 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01497262 | Feb 2012 → Apr 2014 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01499667 | Sep 2011 → Nov 2012 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01201356 | Sep 2010 → Oct 2018 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01199861 | Aug 2010 → May 2011 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT01127750 | May 2010 → Oct 2011 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00731692 | Jul 2008 → Jun 2015 | primary progressive multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00662649 | Feb 2008 → Jun 2011 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00355134 | Jun 2006 → Jun 2011 | multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00340834 | May 2006 → Jul 2011 | relapsing-remitting multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00289978 | Jan 2006 → Jul 2009 | relapsing-remitting multiple sclerosis | Novartis | Completed | No outcome recorded |
| Phase 3 | NCT00239876 | May → Dec 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099801 | Jan 2005 → Mar 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00239863 | May 2004 → May 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00098735 | Apr 2004 → Apr 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00239811 | Apr 2004 → May 2006 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00099736 | May 2003 → Sep 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00239785 | Apr 2003 → Apr 2005 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 422 trials | ||||||
| Phase 4 | NCT05307731 | Mar 2022 → Mar 2026 overdue | type 2 diabetes mellitus | General Hospital of Shenyang Military Region | Recruiting | No outcome recorded |
| Phase 4 | NCT04667949 | Feb 2021 → Mar 2025 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT04480853 | Oct 2020 → Sep 2027 expected | multiple sclerosis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT03535298 | Jan 2019 → Jul 2027 expected | relapsing-remitting multiple sclerosis | The Cleveland Clinic | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03257358 | Sep 2017 → Mar 2019 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02575365 | Feb 2016 → Jan 2017 | — | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 4 | NCT02373098 | Mar 2015 → Jan 2017 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02232061 | Sep 2014 → Jan 2020 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02325440 | Mar 2014 → Apr 2016 | relapsing-remitting multiple sclerosis | University Hospital Muenster | Unknown | No outcome recorded |
| Phase 4 | NCT02048072 | Jul 2013 → Jun 2015 | dysautonomia, multiple sclerosis | Jochen Vehoff | Completed | No outcome recorded |
| Phase 4 | NCT01621269 | Jun 2013 → Jun 2014 | multiple sclerosis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 4 | NCT01755871 | Jan 2013 → Jan 2016 | relapsing-remitting multiple sclerosis | Heinrich-Heine University, Duesseldorf | Terminated | No outcome recorded |
| Phase 4 | NCT01578330 | Oct 2012 → Apr 2015 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01623596 | Jun 2012 → Jul 2015 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01585298 | Apr 2012 → Dec 2016 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01534182 | Jan 2012 → Jun 2013 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01498887 | Dec 2011 → Dec 2015 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01420055 | Aug 2011 → Jun 2013 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01333501 | May 2011 → Sep 2015 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01317004 | May 2011 → Jun 2014 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01310166 | Feb 2011 → Jul 2012 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01216072 | Aug 2010 → Aug 2012 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04718064 | Feb → Oct 2021 | stroke disorder | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 15 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05145621 Comparator | Oct 2015 → Jan 2016 | — | Alembic Pharmaceuticals Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02193217 Comparator | ? → Dec 2014 | relapsing-remitting multiple sclerosis | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT05285878 Comparator | Jul 2022 → Jun 2027 expected | chronic kidney disease, chronic transplant rejection, renal fibrosis | The Methodist Hospital Research Institute | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT01779700 Comparator | Jan 2013 → Aug 2016 | schizophrenia | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT00273364 Comparator | Nov 2005 → Jan 2017 | multiple sclerosis | Northwestern University | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02939079 Background | Apr 2015 → Sep 2016 | multiple sclerosis | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT06408259 Comparator | Apr 2025 → Apr 2031 expected | relapsing-remitting multiple sclerosis | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 3 | NCT05123703 Comparator | May 2022 → Jun 2025 overdue | relapsing-remitting multiple sclerosis | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04926818 Comparator | Oct 2021 → Mar 2026 overdue | multiple sclerosis | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT02769689 Background | Jun 2019 → Jun 2024 | multiple sclerosis | University Hospital, Clermont-Ferrand | Unknown | No outcome recorded |
| Phase 4 | NCT03345940 Comparator | Apr 2017 → Oct 2019 | relapsing-remitting multiple sclerosis | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Terminated | No outcome recorded |
| Phase 4 | NCT02720107 Background | May → Nov 2016 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02342704 Comparator | Nov 2014 → May 2016 | relapsing-remitting multiple sclerosis | Biogen | Terminated | No outcome recorded |
| Phase 4 | NCT01705236 Background | Aug 2012 → Feb 2019 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT01436643 Background | Nov 2011 → Sep 2013 | depressive disorder, relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Press releases naming this drug 18 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-09-21 | Novartis Pharmaceuticals | Novartis plans to petition the U.S. Supreme Court to uphold validity of the Gilenya® (fingolimod) dosing regimen patent novartis.com ↗ |
| 2022-06-21 | Novartis Pharmaceuticals | Novartis plans to petition the U.S. Court of Appeals for the Federal Circuit for further review to uphold validity of the Gilenya® (fingolimod) dosing regimen patent novartis.com ↗ |
| 2022-01-04 | Novartis Pharmaceuticals | Novartis announces U.S. Court of Appeals for the Federal Circuit (CAFC) upholds validity of Gilenya® (fingolimod) dosage regimen patent novartis.com ↗ |
| 2020-08-17 | Novartis Pharmaceuticals | Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent novartis.com ↗ |
| 2019-07-19 | Novartis Pharmaceuticals | Novartis key multiple sclerosis product Gilenya® approved in China novartis.com ↗ |
| 2019-05-10 | Novartis Pharmaceuticals | Novartis data at AAN show Gilenya® is the first and only disease-modifying therapy with proven superiority versus glatiramer acetate in relapsing remitting MS novartis.com ↗ |
| 2018-11-29 | Novartis Pharmaceuticals | Novartis announces EU approval of Gilenya® for children and adolescents with MS, making it the first and only oral disease-modifying treatment for these patients in Europe novartis.com ↗ |
| 2018-10-10 | Novartis Pharmaceuticals | Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya® over Copaxone® in patients with relapsing remitting multiple sclerosis novartis.com ↗ |
| 2018-09-21 | Novartis Pharmaceuticals | Novartis receives positive CHMP opinion for Gilenya® for the treatment of children and adolescents with MS, marking a major medical advance for young MS patients in Europe novartis.com ↗ |
| 2018-09-12 | Novartis Pharmaceuticals | Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS novartis.com ↗ |
| 2018-05-12 | Novartis Pharmaceuticals | Novartis announces FDA approval of Gilenya® as the first disease-modifying therapy for pediatric relapsing multiple sclerosis novartis.com ↗ |
| 2017-10-28 | Novartis Pharmaceuticals | Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya® vs. interferon beta-1a novartis.com ↗ |
| 2017-09-05 | Novartis Pharmaceuticals | Novartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS novartis.com ↗ |
| 2017-04-24 | Novartis Pharmaceuticals | Novartis real-world data at AAN confirms benefit of Gilenya® on four key measures of disease activity in relapsing MS novartis.com ↗ |
| 2016-09-16 | Novartis Pharmaceuticals | New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years novartis.com ↗ |
| 2015-10-08 | Novartis Pharmaceuticals | Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years novartis.com ↗ |
| 2015-04-21 | Novartis Pharmaceuticals | Data at AAN showed Gilenya® high efficacy in achieving 'no evidence of disease activity' in previously-treated highly-active MS patients novartis.com ↗ |
| 2015-04-13 | Novartis Pharmaceuticals | Gilenya® data at AAN to highlight Novartis leadership in innovation with new MS assessment methods to benefit patients and physicians novartis.com ↗ |
Evidence & citations 19 cited values
Every value below carries the sentence it was read from. 93 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fingolimod | “Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer...” NCT00273364 ↗70“Patients with acute unilateral ON, occurring as a clinically isolated syndrome or MS relapse, were randomized to 6 months of treatment with 0.5 mg oral fingolimod or...” PMID 32126977 ↗ Mar 2020 “Fingolimod (FTY720) has previously shown clinical efficacy in phase II/III studies of predominantly Caucasian populations with multiple sclerosis (MS).” PMID 22354739 ↗ Feb 2012 “Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS” NCT02048072 ↗ “Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.” PMID 16971719 ↗ Sep 2006 “The patients of this group were treated with Fingolimod 0.5mg per day, in addition to guideline based treatment.” NCT05307731 ↗ “Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse-onset multiple sclerosis” PMID 26827074 ↗ Jan 2016 “Between Natalizumab and Fingolimod Treatments in Patients With Multiple Sclerosis” NCT02769689 ↗ “Fingolimod 0.5 mg by mouth once daily for 7 days.” NCT01585298 ↗ “Gilenya (fingolimod)” NCT03535298 ↗ |
| Known as | Fingolimod (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | Fingolimod accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | Fingolimod hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | Fingolimod hydrochlorid | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | Fingolimod Hydrochloride | “Drug: Fingolimod Hydrochloride” NCT03941743 ↗1“Drug: Fingolimod Hydrochloride” NCT03943498 ↗ |
| Known as | Fingolimod mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | FTY | “Leukocyte sequestration is an established therapeutic concept in multiple sclerosis (MS) as represented by the trafficking drugs natalizumab (NAT) and fingolimod (FTY).” PMID 30050529 ↗ Jul 2018 |
| Known as | FTY-720 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | FTY720 | “METHODS: This multicenter, double-blind, Phase IIb, randomized study evaluated the safety and efficacy of 5 mg FTY720 (n=87; Group 1) vs. 2.5 mg FTY720 (n=90; Group 2) vs....” PMID 17984842 ↗ Oct 200726“Fingolimod (FTY720) is a new oral immunomodulating agent under evaluation for the treatment of relapsing multiple sclerosis.” PMID 16971719 ↗ Sep 2006 “FTY720 (Gilenya) is an orally active modulator of four of the five sphingosine-1 phosphate(S1P) receptors.” NCT02061137 ↗ “The sphingosine-1-phosphate receptor regulators Fingolimod (FTY720) is an effective immunology modulator” NCT04280588 ↗ “Fingolimod, a sphingosine-1-phosphate receptor regulator (FTY720), is an effective immunology modulator.” NCT06087965 ↗ “Fingolimod (FTY720, approved as Gilenya™ ) is a sphingosine-1-phosphate (S1P) receptor modulator” NCT01779700 ↗ “Treatment With Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis” NCT01310166 ↗ “Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.” PMID 23531349 ↗ Mar 2013 “Participants received 0.5 mg FTY720 (fingolimod) orally once daily for 12 months.” NCT01498887 ↗ “Fingolimod (FTY720)” NCT01625182 ↗ “fingolimod (FTY720)” NCT00731523 ↗ “Fingolimod, FTY720” NCT01578330 ↗ |
| Known as | FTY720, fingolimod hydrochloride, | “FTY720, fingolimod hydrochloride,” NCT01633112 ↗ |
| Known as | Gilenia | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Known as | Gilenya | “Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer...” NCT00273364 ↗11“Patients randomized to fingolimod will also receive fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given...” NCT04675762 ↗ “This is a single-institution, open-labeled study using fingolimod (FTY720/Gilenya) in patients with non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC)” NCT06424067 ↗ “All patients received standard management alone (control participants) or combined with fingolimod (FTY720, Gilenya), 0.5 mg, orally for 3 consecutive days.” PMID 25003359 ↗ Sep 2014 “Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days” NCT02956200 ↗ “Evaluation of the Autonomic Nervous System During First-dosing With 0.5mg of Fingolimod (Gilenya) in Patients With Relapsing-remitting MS” NCT02048072 ↗ “early therapeutic intervention with fingolimod (Gilenya ®) after optic neuritis(ON) has a favorable visual outcome” NCT01647880 ↗ “FTY720 (Gilenya) is an orally active modulator of four of the five sphingosine-1 phosphate(S1P) receptors.” NCT02061137 ↗ “Fingolimod (FTY720, approved as Gilenya™ ) is a sphingosine-1-phosphate (S1P) receptor modulator” NCT01779700 ↗ “fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days” NCT04718064 ↗ “oral fingolimod (Gilenya, Novartis)” NCT04629872 ↗ |
| Known as | Gilenya (fingolimod) | “Gilenya (fingolimod)” NCT03535298 ↗ |
| Known as | Tascenso odt | ChEMBL registry synonym — accepted as the source's own label CHEMBL314854 ↗ |
| Action | Activate | “FTY720 acts as 'super agonist' on the S1P receptor on thymocytes and lymphocytes, inducing uncoupling/internalization of that receptor.” NCT02061137 ↗ |
| Modality | Small molecule | “Fingolimod is a small molecule derived from myriocin” NCT06424067 ↗ |
| Route | Oral | “Patients self-administered fingolimod 1.25 mg capsules orally once daily.” NCT00289978 ↗ |
| Target | RHOA | “a sphingosine 1-phosphate receptor modulator and a RhoA inhibitor (2)” NCT05285878 ↗ |